000K utf8 1100 $c2024 1500 eng 2050 urn:nbn:de:gbv:8:3-2025-00371-2 2051 10.3390/diagnostics14060602 3000 Eichhorn, Anna 3010 Bäumler, Carina 3010 Grobe, Olaf 3010 Gutsmann, Imke 3010 Krumbholz, Andi 3010 Müller, Sina 3010 Neumann, Franziska 3010 Schlüter, Frieda 4000 Assessment of the Diagnostic Performance of Fully Automated Hepatitis E Virus (HEV) Antibody Tests$hMDPI AG [Eichhorn, Anna] 4030 $nMDPI AG 4209 The detection of anti-hepatitis E virus (HEV) antibodies contributes to the diagnosis of hepatitis E. The diagnostic suitability of two automated chemiluminescence immunoassays (CLIAs, LIAISON® MUREX Anti-HEV IgG/Anti-HEV IgM test, DiaSorin) was assessed by comparison with the results of a combination of enzyme immunoassays and immunoblots (recomWell HEV IgG/IgM ELISA, recomLine HEV IgG/IgM, MIKROGEN). Samples with a deviating result were analyzed with the WANTAI ELISAs. Compared to the recomWell ELISAs, the Anti-HEV IgG CLIA had a percentage overall agreement (POA) of 100% (149/149; 95% CI: 97.5-100%) and the Anti-HEV IgM CLIA had a POA of 83.3% (85/102; 95% CI: 74.9-89.3%); considering the recomLine HEV IgM results, the POA was 71.7% (38/53; 95% CI: 58.4-82%). The WANTAI test confirmed 52.9% (9/17) of negative CLIA IgMs; HEV RNA was not detectable. Since acute infection with the Epstein-Barr virus (EBV) or human cytomegalovirus (CMV) may influence the results of other serological assays, HEV antibodies were examined in 17 EBV and 2 CMV patients: One had an isolated and probably unspecific HEV IgM in the CLIA, as HEV RNA was not detectable. Both CLIAs are well suited for HEV diagnostics, but isolated IgM should be confirmed. An acute EBV/CMV infection can influence HEV serodiagnostics. 4950 https://doi.org/10.3390/diagnostics14060602$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2025-00371-2$xR$3Volltext$534 4961 https://macau.uni-kiel.de/receive/macau_mods_00005902 5051 610 5550 Hepatitis E virus 5550 Immunoassays 5550 Percentage Agreement 5550 Polyclonal Stimulation